COST-CONSEQUENCE ANALYSIS OF EMICIZUMAB PROPHYLAXIS FOR SEVERE HEMOPHILIA A PATIENTS WITHOUT INHIBITORS

被引：0
|
作者：
Cortesi, P. A. [1 ]
Castaman, G. [2 ]
Mantovani, L. G. [1 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Azienda Osped Univ Careggi, Florence, Italy
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRO40
引用
收藏
页码：S696 / S696
页数：1
相关论文
共 50 条
  • [41] Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
    Giuffrida, Gaetano
    Nicolosi, Daniela
    Condorelli, Annalisa
    Markovic, Uros
    Di Raimondo, Francesco
    [J]. BLOOD, 2021, 138
  • [42] Multicenter retrospective and prospective analysis of emicizumab and FVIII prophylaxis in children with severe hemophilia A
    Hassan, Tamer
    Lotfy, Gehan
    Elalfy, Omar
    Amin, Mervat
    Elmasry, Zahraa
    Elhawary, Eslam
    Darwish, Ahmed
    Elalfy, Mohsen
    [J]. HAEMOPHILIA, 2024, 30 : 222 - 223
  • [43] Emicizumab Prophylaxis in Patients with Severe Hemophilia A: Insights from A Resource Limited Country
    Borhany, Munira
    Arshad, Aisha
    Qureshi, Heeba
    Nadeem, Rukhshanda
    Jamal, Arif
    Khan, Raheel Ahmed
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2024, 30
  • [44] EMICIZUMAB IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS - EXPERIENCE OF A PORTUGUESE CENTRE
    Pestana, J. S. G.
    Peixoto, C.
    Camara, C.
    Correia, C. J.
    Felix, J.
    Pires, F.
    Pereira, A.
    Rodrigues, F.
    Afonso, P.
    Rocha, E.
    Catarino, C.
    [J]. HAEMOPHILIA, 2023, 29 : 107 - 107
  • [45] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
    Cortesi, P. A.
    Castaman, G.
    Trifiro, G.
    Ferrario, M.
    Improta, G.
    Mazzaglia, G.
    Molinari, A. C.
    Mantovani, L. G.
    [J]. VALUE IN HEALTH, 2019, 22 : S845 - S845
  • [46] DIRECT COMPARISON OF PROPHYLAXIS COST IN PATIENTS WITH SEVERE HEMOPHILIA A WITH AND WITHOUT INHIBITORS WITH HEMOSTATIC AGENTS VERSUS THE USE OF EMICIZUNIAB IN GUATEMALA
    Leal Lopez, A. M.
    Oliva Lara, S. C.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S181 - S181
  • [47] Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe
    Mancuso, Maria Elisa
    Castaman, Giancarlo
    Pochopien, Michal
    Aballea, Samuel
    Drzewiecka, Aleksandra
    Hakimi, Zalmai
    Nazir, Jameel
    Fatoye, Francis
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1068 - 1075
  • [48] Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis
    Santagostino, Elena
    Mancuso, Maria Elisa
    Novembrino, Cristina
    Boscolo, Massimo Anzoletti
    Clerici, Marigrazia
    Pasta, Gianluigi
    Solimeno, Luigi Piero
    Peyvandi, Flora
    [J]. BLOOD, 2017, 130
  • [49] Cost-consequence analysis for the handmaster in the Netherlands
    Nuijten, MJ
    Engelfriet, P
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A151 - A151
  • [50] EMICIZUMAB PROPHYLAXIS IN INFANTS WITH SEVERE HEMOPHILIA A: MANAGEMENT OF 6 CASES
    Wang, Cassandra
    Kizilocak, Hande
    Young, Guy
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69
12345